As of Jun 29, 2018 Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB) Sellers Reduced Their Shorts By 0.01%

June 29, 2018 - By Charla Downs

It was reported a decrease on Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB)’s shorted shares with 0.01%. FINRA issued in June ZLAB’s total 1.85 million shorted shares. The 1.86 million previous shares are down with 0.01%. Former ZLAB’s position will need 31 days to restore. It has 60,300 average volume. Zai Lab Limited – American Depositary Shares’s shorted shares float is 65.15%.

ZLAB reached $23.0386 during the last trading session after $0.2486 change.Currently Zai Lab Limited is after 0.00% change in last June 29, 2017. ZLAB has 11,052 shares volume. The stock underperformed the S&P 500 by 12.57%.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China.The firm is worth $1.17 billion. The Company’s drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus.Last it reported negative earnings.

More recent Zai Lab Limited (NASDAQ:ZLAB) news were published by, and The first one has “The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines” as a title and was published on June 03, 2018. The next is “Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer” on June 05, 2018. And last was published on June 29, 2018, called “Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line …”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: